Executive Orders aim to show progress on drug pricing

Early in the current White House administration, exceptionally strong rhetoric around drug pricing from President Donald Trump rattled pharma markets, as investors feared new measures to control drug prices were imminent.

Over time, as analysts became accustomed to the President’s unique communication style, such fears subsided, and the industry’s approach to pricing continued  essentially as before.

Now the issue has been somewhat revived. Unable to progress change through the US Congress, the president has signed four Executive Orders in a bid to show: “historic action to deliver lower prescription drug prices,” has been taken.